You are here

Development and Commercialization of an Innovative Rapid HIV-1 Incidence Assay

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI114365-01
Agency Tracking Number: R43AI114365
Amount: $195,490.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4900 NE 122ND AVE, PORTLAND, OR, 97230-1049
DUNS: 16504083
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (503) 459-4159
Business Contact
Phone: (503) 459-4159
Research Institution
DESCRIPTION (provided by applicant): The objective of this project is to develop a commercially viable point of care Rapid HIV-1 Incidence Assay and establish its suitability for determination of recency of HIV-1 infection in whole blood, plasma, serum specimens for epidemiological, research and surveillance purposes. It is further intended to determine the feasibility of the application of the assay to dried blood spot and oral fluid specimens. Potential development of the assay into a combined incidence/diagnostic assay including applicable regulatory submissions is not intended until Phase II of the project. Recent advances in development of accurate assays for distinguishing recent from long-term HIV infections have been limited to complex laboratory based assays. However, many resource constrained countries and laboratories need to be able to estimate HIV incidence rates in populations, but do not have ready access to full laboratory facilities. The proposed Rapid HIV-1 Incidence Assay, once establ

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government